 | |
| Clinical data | |
|---|---|
| Other names | KX-826; KX826 |
| Routes of administration | Topical[1] |
| Drug class | Nonsteroidal antiandrogen;Androgen receptor antagonist |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C21H15F5N4O2S |
| Molar mass | 482.43 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pyrilutamide (developmental code nameKX-826) is anonsteroidal antiandrogen (NSAA) which is under development for the treatment ofandrogenic alopecia (pattern hair loss) andacne.[1][2][3] The drug is being developed by Suzhou Kintor Pharmaceuticals.[1] As of February 2025, it is inphase 3clinical trials for androgenic alopecia andphase 2 trials for acne.[1] The drug was also under development for the treatment ofdiabetic foot ulcers, but development for this indication was discontinued.[1]
Pyrilutamide is aselective and high-affinitysilentantagonist of theandrogen receptor (AR). It has an affinity (IC50Tooltip half-maximal inhibitory concentration) of 0.28 nM, relative to 3.1 nM in the case ofbicalutamide.[3]